Caution needed over wonder-drug company


Is British Biotech the next Glaxo or just another speculative bubble? The City is excitedly talking about it in the revered tones as the former. The success of clinical trials on its BB-2516 cancer drug sent the shares soaring to pounds 21 yesterday before falling back again. The finance director, Jim Noble, tried vainly to dampen the hysteria by warning that the drug had many obstacles to overcome before it becomes commercially available, possibly in three years, but he failed. Everyone likes a stock market wonder company and in British Biotech we seem to have one.

Mr Noble's caution is understandable as well as reponsible. It prevents millions of cancer sufferers being offered false hope. It also allows the company to continue its development without being saddled with the wonder-drug tag. But the City is not easily side-tracked from the sniff of wealth beyond the dreams of avarice and the talk is of huge potential for the drug and huge share price potential for the company.

While extremely encouraging, the cancer data is very preliminary. However, British Biotech is more than a one-drug company. What really impresses analysts is the range of drugs the company has under development, all with enormous potential. This weekend British Biotech will release progress reports on another drug, BB-10010, which protects the immune system of patients undergoing chemotherapy. Its arthritis drug, BB 2983, goes into clinical trials next year, with Glaxo Wellcome itself picking up the bill. Glaxo Wellcome is also paying for phase-two clinical trials for British Biotech's asthma drug. While health regulators need to be 100 per cent sure of a drug to give it approval, the stock market is not so demanding. If there is an even chance of British Biotech getting at least some of its products to market it will be enough to drive the share price, say analysts.

Gone are the days when the big pharmaceutical companies threw expensive combinations of drugs at mice and men. British Biotech, with its intellectual base in Oxford University, sells itself as a company trying to provide solutions to the root causes of complaints which either affect millions or are very expensive to treat. Cancer has always been the great Holy Grail of modern medicine and the potential market is enormous if the drugs are good enough. With royalty agreements already in place Glaxo Wellcome is already hovering on the sidelines. For the time being UK institutions are so convinced of the potential that anything less than a silly price would fail to tempt them. The upside for this stock still looks huge.

A first step towards reining in Murdoch

Could it be that the year-long campaign by cable operators to rein in Rupert Murdoch's BSkyB has finally borne fruit? On the face of it, yesterday's announcement that the Office of Fair Trading is to investigate the terms of Sky's supply of programming to cable operators is a sign that the Government (the DTI and OFT at any rate) is finally taking Mr Murdoch's dominant position seriously.

There is much at risk for BSkyB, which has acquired a powerful position in the UK television market by offering film and sport unavailable elsewhere. Cable operators, following efforts to develop their own sources of Hollywood product and top-level sport, gave in, and accepted that they would have to buy wholesale from Sky.

The problem from the cable operators' point of view was that BSkyB could set the price and the terms of supply. It could bundle channels together, obliging them to take both movie channels, for example, if they wanted to offer their subscribers Disney. A number of "informal undertakings" between the OFT and BSkyB failed to offer much remedy. Even after Sky's channels were ostensibly meant to be offered a la carte, cable operators found that they still had to take at least one movie channel if they wanted to get Disney.Typically for a company run along Mr Murdoch's preferred lines, every concession by BSkyB seemed to hide yet another condition. For every one issue on which the company apparently gave way, another two would emerge - vintage Murdoch.

This has become more than just a commercial battle. Reining in Mr Murdoch has become an issue of public policy in the light of the advent of digital technology. BSkyB cannot be allowed to leverage its analogue dominance to take over the digital world as well. The OFT inquiry is a first step: wholesale programming must be available on transparent, unbundled terms. Next, the anti-competitive clauses of some of Sky's contracts (with Nynex, Telewest and the Premier League, for a start) must be quashed. Down the road, Sky's dominance of conditional access must be whittled down.

Finally, with the likely full-scale commercialisation of the BBC, the consolidation of the ITV sector and the advent of digital, it may even be time to bring BSkyB under more direct regulatory control. Why should Sky, unlike all the monopoly ITV companies, be able to avoid full and frank regulation? Clearly these are not matters for the OFT but at least it has realised that someone has to make a start.

Granada moves closer to its goal

Less than two weeks into the Forte takeover battle and the Granada share price is already beginning to creep back from the drubbing it received in the immediate aftermath of the company's pounds 3.2bn bid. Gerry Robinson, chief executive, still has a task to perform in convincing the City of the merits of this takeover, but he is beginning to get there. In the meantime Forte looks as vulnerable as ever. There is enormous disillusion among institutional shareholders with this company. If Mr Robinson's task is still a hard one, Forte's is doubly so.

Forte's first formal defence document is out next week but unless there is something unexpected to pull out of the hat it is hard to see how it can further the arguement very much. The track record is poor. While it might be possible to put some fancy sum-of-the-parts valuation on the company, such exercises are only meaningful if management is prepared to put the valuation with a wholesale breakup. Does Sir Rocco Forte really want to do that? He seems prepared to go further than Granada on this front but not the whole hog.

The other traditional strategy in a bid defence is to attack the bidder. Here again Forte is going to find it hard going. Unless there is an achilles' heel we do not know about, Forte is not going to be able to fault Granada on financial performance. In accounting terms, too, the company looks squeaky-clean.

The commercial logic of the deal is easier ground but again the core Forte businesses of roadside catering and inexpensive overnight accommodation fit neatly into the Granada group. Sir Rocco may yet surprise us but at this stage it looks bad for him. A little bit more on the offer price and Granada is home and dry.

More than 90 years of car history are coming to an end with the abolition of the paper car-tax disc
newsThis and other facts you never knew about the paper circle - completely obsolete today
people'I’d rather have Fred and Rose West quote my characters on childcare'
Life and Style
The new Windows 10 Start Menu
Arts and Entertainment
There has been a boom in ticket sales for female comics, according to an industry survey
comedyFirst national survey reveals Britain’s comedic tastes
Bruce Chatwin's novel 'On the Black Hill' was set at The Vision Farm
travelOne of the finest one-day walks you could hope for - in Britain
footballManchester City 1 Roma 1: Result leaves Premier League champions in danger of not progressing
Arts and Entertainment
Gay and OK: a scene from 'Pride'
filmsUS film censors have ruled 'Pride' unfit for under-16s, though it contains no sex or violence
Life and Style
Magic roundabouts: the gyratory system that has excited enthusiasts in Swindon
motoringJust who are the Roundabout Appreciation Society?
Arts and Entertainment
Hilary North's 'How My Life Has Changed', 2001
booksWell it was good enough for Ancient Egyptians and Picasso...
ebooksAn unforgettable anthology of contemporary reportage
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Trainee Recruitment Consultant - Birmingham - Real Staffing

£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...

Trust Accountant - Kent

NEGOTIABLE: Austen Lloyd: TRUST ACCOUNTANT - KENTIf you are a Chartered Accou...

Graduate Recruitment Consultant - 2013/14 Grads - No Exp Needed

£18000 - £20000 per annum + OTE £30000: SThree: SThree are a global FTSE 250 b...

Law Costs

Highly Competitive Salary: Austen Lloyd: CITY - Law Costs Draftsperson - NICHE...

Day In a Page

Ebola outbreak: The children orphaned by the virus – then rejected by surviving relatives over fear of infection

The children orphaned by Ebola...

... then rejected by surviving relatives over fear of infection
Pride: Are censors pandering to homophobia?

Are censors pandering to homophobia?

US film censors have ruled 'Pride' unfit for under-16s, though it contains no sex or violence
The magic of roundabouts

Lords of the rings

Just who are the Roundabout Appreciation Society?
Why do we like making lists?

Notes to self: Why do we like making lists?

Well it was good enough for Ancient Egyptians and Picasso...
Hong Kong protests: A good time to open a new restaurant?

A good time to open a new restaurant in Hong Kong?

As pro-democracy demonstrators hold firm, chef Rowley Leigh, who's in the city to open a new restaurant, says you couldn't hope to meet a nicer bunch
Paris Fashion Week: Karl Lagerfeld leads a feminist riot on 'Boulevard Chanel'

Paris Fashion Week

Lagerfeld leads a feminist riot on 'Boulevard Chanel'
Bruce Chatwin's Wales: One of the finest one-day walks in Britain

Simon Calder discovers Bruce Chatwin's Wales

One of the finest one-day walks you could hope for - in Britain
10 best children's nightwear

10 best children's nightwear

Make sure the kids stay cosy on cooler autumn nights in this selection of pjs, onesies and nighties
Manchester City vs Roma: Five things we learnt from City’s draw at the Etihad

Manchester City vs Roma

Five things we learnt from City’s Champions League draw at the Etihad
Martin Hardy: Mike Ashley must act now and end the Alan Pardew reign

Trouble on the Tyne

Ashley must act now and end Pardew's reign at Newcastle, says Martin Hardy
Isis is an hour from Baghdad, the Iraq army has little chance against it, and air strikes won't help

Isis an hour away from Baghdad -

and with no sign of Iraq army being able to make a successful counter-attack
Turner Prize 2014 is frustratingly timid

Turner Prize 2014 is frustratingly timid

The exhibition nods to rich and potentially brilliant ideas, but steps back
Last chance to see: Half the world’s animals have disappeared over the last 40 years

Last chance to see...

The Earth’s animal wildlife population has halved in 40 years
So here's why teenagers are always grumpy - and it's not what you think

Truth behind teens' grumpiness

Early school hours mess with their biological clocks
Why can no one stop hackers putting celebrities' private photos online?

Hacked photos: the third wave

Why can no one stop hackers putting celebrities' private photos online?